Remedium Lifecare Ltd — Updates, 05-05-2025: Company Update

Remedium Lifecare has announced a rights issue priced at ₹1 per share (61:50 ratio), receiving a 26% subscription within two days. The capital raised will fund R&D expansion, working capital, and global contract manufacturing growth in the CDMO space. This move supports the company’s recent ₹182.7 crore multi-year export order from a UK pharmaceutical distributor, strengthening its position as a global supplier of pharmaceutical intermediates in key therapeutic areas. The rights issue aims to boost financial health and operational capabilities, driving long-term growth and international market presence.